Table 2.
SNPs related to Response to Induction Therapy, Rapid COJEC in High-Risk NB.
| Gene | SNP | Results | Involved Candidate Drug * | ||
|---|---|---|---|---|---|
| Genotype | OR | Association | |||
| mCR vs non mCR | |||||
| ABCC2 | rs3740066 | GG | 1.79 | ↑ efficacy | Platinum-compounds |
| MAP3K1 | rs726501 | AG | 2.87 | ↑ efficacy | |
| NQO2 | rs1143684 | TT | 1.14 | ↑ efficacy | Cyclophosphamide |
| VEGFA | rs2010963 | GG | 1.23 | ↑ efficacy | |
| ABCB1 | rs10276036 | TT | 0.67 | ↓ efficacy | |
| SLCO1B1 | rs4149056 | TC | 0.64 | ↓ efficacy | |
| CBR3 | rs8133052 | GG | 0.53 | ↓ efficacy | |
| VDR | rs1544410 | GA | 0.68 | ↓ efficacy | Etoposide |
mCR: metastatic Complete Response; non mCR: non metastatic Complete Response. OR: Odds Ratio. SNP: Single Nucleotide Polymorphism. * According to literature and PharmGKB. Total number of patients, N = 41. ↑ means “increase” and ↓ “decrease”.